Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer

NCT03645148 is registered in ClinicalTrials.gov with Zhejiang Provincial People's Hospital as lead sponsor.

NCT NCT03645148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03645148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
Lead sponsor
Zhejiang Provincial People's Hospital
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2017
Completion date
April 1, 2021
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic carcinoma